Nordic Capital and Permira's Progress on Bavarian Nordic Acquisition
In a significant move towards enhancing their strategic position in the pharmaceutical and vaccine industry, Nordic Capital and Permira have successfully obtained final regulatory approval for their takeover offer of Bavarian Nordic A/S. This announcement follows previous public disclosures and reflects a proactive approach to solidifying their interests in a company renowned for its innovative vaccines.
Regulatory Approval Secured
The Offeror, Innosera ApS, which is under the control of Nordic Capital Fund XI and managed by Permira, recently confirmed that it has received merger control clearance from the European Commission. This critical milestone marks an important step in the acquisition process by ensuring that all necessary regulatory approvals have been successfully navigated. With these approvals in hand, the pathway to complete the takeover is now clearer.
Conditions of the Offer
The completion of the takeover remains contingent upon the satisfaction of specific conditions outlined in the offer document. One of the primary requirements is achieving a minimum acceptance threshold of 75% of the shares in Bavarian Nordic, excluding treasury shares. This condition underscores the necessity for active participation from Bavarian Nordic's shareholders.
Timelines and Expectations
The offer period for shareholders to accept the takeover is set to expire shortly, urging those yet to respond to act before the deadline. Bavarian Nordic has communicated that the offer will terminate on October 14, and shareholders are encouraged to submit their acceptance to ensure their shares are included in the deal. Should the required acceptance conditions be satisfied, the Offeror anticipates the finalization of the takeover by mid-November.
Engagement with Shareholders
To assist shareholders in making informed decisions, Bavarian Nordic has made available comprehensive documents related to the offer. These include an offer document and a board statement that proposes the acceptance of the offer. It’s advisable for shareholders to thoroughly review these materials to understand the implications of the offer fully.
About Bavarian Nordic
Bavarian Nordic is a global leader in vaccine development, with a strong commitment to improving health outcomes through innovative infectious disease prevention. The company has established itself as a preferred provider of vaccines for mpox and smallpox, playing a pivotal role in public health preparedness. Additionally, their robust portfolio of travel vaccines reflects their dedication to expanding immunization options globally.
Shareholder Communication and Contact Information
For further inquiries, shareholders and interested parties can reach out to the investor relations team. Rolf Sass Sørensen serves as the Vice President of Investor Relations, with direct lines available for European contacts. In the US, Graham Morrell stands ready to assist. This structured communication underscores the importance of transparency during the acquisition process.
Future of Bavarian Nordic Post-Acquisition
The anticipated acquisition by Nordic Capital and Permira could catalyze strategic innovation within Bavarian Nordic, allowing for enhanced research capabilities, expanded market reach, and potentially new product developments. Industry experts are closely monitoring this acquisition, recognizing the value it could bring to public health sectors globally.
Frequently Asked Questions
What is the status of the takeover offer for Bavarian Nordic?
The takeover offer by Nordic Capital and Permira has received final regulatory approval, enhancing the likelihood of completion.
What are the key conditions for the completion of the takeover?
The Offeror must secure a minimum acceptance of 75% of the issued shares to finalize the acquisition.
When does the offer period expire for shareholders?
The offer period for shareholders to accept the takeover will expire on October 14.
What is Bavarian Nordic's reputation in the vaccine industry?
Bavarian Nordic is recognized as a leader in vaccine innovation, particularly in the areas of public health preparedness with vaccines for mpox and smallpox.
Who can shareholders contact for more information?
Shareholders can reach out to Rolf Sass Sørensen or Graham Morrell for any inquiries related to the takeover.
